Press Releases

 
Press Releases
  Date Title and Summary View
Nov 8, 2017
MONROVIA, Calif., Nov. 8, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that data from preclinical studies of XmAb®20717, a PD1 x CTLA4 dual checkpoint inh...
PDF
Nov 7, 2017
MONROVIA, Calif., Nov. 7, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today reported financial results for the third quarter ended September 30, 2017 and provided a review of ...
PDF
Nov 4, 2017
MONROVIA, Calif., Nov. 4, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced the final results from a Phase 2 study of XmAb5871 in patients with active IgG4-RD. Data...
PDF
Nov 1, 2017
MONROVIA, Calif., Nov. 1, 2017 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will present a corporate update at two upcoming conferences: ...
PDF
Oct 31, 2017
MONROVIA, Calif., Oct. 31, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release third quarter 2017 financial results after the market closes on Tuesday,...
PDF
Oct 20, 2017
MONROVIA, Calif., Oct. 20, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the final results from its open-label, Phase 2 study of XmAb®5871 in patients...
PDF
Sep 20, 2017
MONROVIA, Calif., Sept. 20, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will present a corporate update at two upcoming conferences: ...
PDF
Aug 7, 2017
MONROVIA, Calif., Aug. 7, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today reported financial results for the second quarter ended June 30, 2017 and provided a review of busi...
PDF
Aug 2, 2017
MONROVIA, Calif., Aug. 2, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will present a corporate overview at two upcoming conferences: ...
PDF
Jul 31, 2017
MONROVIA, Calif., July 31, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release second quarter 2017 financial results after the market closes on Monday,...
PDF
Page:
1
... NextLast
Xencor © Copyright 2017